Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis.
about
Gene therapy in animal models of rheumatoid arthritis: are we ready for the patients?IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cellsBlood soluble interleukin 1 receptor accessory protein levels are consistently low throughout the menstrual cycle of women with endometriosis.Most recent developments in strategies to reduce the progression of structural changes in osteoarthritis: today and tomorrow.Perspectives on the use of gene therapy for chronic joint diseases.A single-nucleotide polymorphism in the interleukin-1 receptor-associated protein gene is associated with impaired glucose regulation and type 2 diabetes in a case-controlled study.Immunosuppressive exosomes: a new approach for treating arthritis.Inhibition of IL-1 Signaling by Antisense Oligonucleotide-mediated Exon Skipping of IL-1 Receptor Accessory Protein (IL-1RAcP).A potent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis: a comparison with neutralization of mouse TNFalpha.Role of interleukin-1 inhibitors in osteoarthritis: an evidence-based review.Synthesis of self-assembled IL-1Ra-presenting nanoparticles for the treatment of osteoarthritis.Inhibition of TNF alpha during maturation of dendritic cells results in the development of semi-mature cells: a potential mechanism for the beneficial effects of TNF alpha blockade in rheumatoid arthritis.Rheumatoid arthritis: safe and sound.The family of the interleukin-1 receptors.Chitosan/hyaluronic acid/plasmid-DNA nanoparticles encoding interleukin-1 receptor antagonist attenuate inflammation in synoviocytes induced by interleukin-1 beta
P2860
Q24796801-F136E3B4-5C08-4736-B6A0-EE94D4B3A5B5Q28513686-96A86B8D-CA22-41FC-90E0-CCF4E6AB061AQ33811574-BCF63A51-1FB1-4326-8B11-7B0994D59206Q34896866-90DC3A3C-28C5-4BFD-8066-5E0EF91ABCBEQ35151031-DACF286C-258D-40F4-8B6D-21DC361B8C9FQ35803472-CDB8B81F-AFAB-43B2-B1B5-2F3B7E924BF9Q35882794-59EC0E29-F394-4A67-A6E0-2EAE1247706BQ36588937-C27F9DD6-5332-41BA-92F4-067E154BE214Q36735853-46745196-6E79-45A3-B179-AB64C8454FD8Q38006975-A354D9CE-F9F0-4AAE-B002-BAAF7574F094Q38824381-92921613-B50F-405D-AC3C-A88C41D3DA5AQ41809691-9BFC4B53-35FB-4F77-BF6C-2F4437931F00Q45876150-484D5A2F-239A-443D-BF5D-636A1EBCBCD0Q47285858-D20E4428-360C-473A-A868-68F6DE579F28Q57057669-001EB868-E99E-4FA8-98F3-DA717B883E37
P2860
Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Effectiveness of the soluble f ...... in collagen-induced arthritis.
@en
type
label
Effectiveness of the soluble f ...... in collagen-induced arthritis.
@en
prefLabel
Effectiveness of the soluble f ...... in collagen-induced arthritis.
@en
P2093
P2860
P356
P1476
Effectiveness of the soluble f ...... in collagen-induced arthritis.
@en
P2093
Bennink MB
Dmitriev IP
Joosten LA
Loesberg WA
van de Loo FA
van den Berg WB
P2860
P304
P356
10.1002/ART.11234
P577
2003-10-01T00:00:00Z